TITLE

Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis

AUTHOR(S)
Blanshard, Christine; Shanson, David C.; Gazzard, Brian G.; Blanshard, C; Shanson, D C; Gazzard, B G
PUB. DATE
February 1997
SOURCE
International Journal of STD & AIDS;Feb1997, Vol. 8 Issue 2, p124
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Pilot studies of the safety and efficacy of 3 drugs thought to have anticryptosporidial activity were carried out to determine whether any of them are suitable for large-scale clinical trials. Open studies of the use of azithromycin, letrazuril and paromomycin in patients with acquired immunodeficiency syndrome (AIDS) and confirmed cryptosporidial diarrhoea for at least a month. Azithromycin 500 mg daily was ineffective. Letrazuril 150-200 mg daily was associated with an improvement in symptoms in 40% of patients treated and cessation of excretion of cryptosporidial oocysts in the stool in 70%; however biopsies remained positive. Paromomycin therapy was associated with a complete resolution of diarrhoea in 60% of patients treated and some improvement in symptoms in a further 5% but it did not eliminate the infection. None of the drugs had any major toxicities. Dose escalation studies of azithromycin should be performed. Letrazuril should be further investigated for efficacy in double-blind placebo-controlled trials. Paromomycin appears to result in prolonged symptomatic remission of cryptosporidial diarrhoea, but has no effect on cryptosporidial cholangitis.
ACCESSION #
22201938

 

Related Articles

  • Data from Thai HIV vaccine study show no significant protective effect against the virus. Roehr, Bob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/31/2009, Vol. 339 Issue 7728, p992 

    The article focuses on a clinical trial of a vaccine developed for human immunodeficiency virus (HIV) in Thailand. The study include 16,402 subjects, aged 18 to 30 years, who were randomized to receive a series of six shots of either placebo or two different HIV vaccines. The two vaccines...

  • Journal of Infectious Diseases: Study confirms early elevated HIV infection risk in some Step Study participants.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article offers information an international HIV-vaccine trial, Step Study, performed on male, which confirmed that male who recieved the experimental vaccine were at higher risk of becoming infected compared to those who received a placebo.

  • Placebo mania. Rothman, Kenneth J. // BMJ: British Medical Journal (International Edition);07/16/96, Vol. 313 Issue 7048, p3 

    Editorial. Comments on the need to remove placebo control as part of standard procedure in drug efficacy studies. Placebo effect as a highly variable but powerful phenomenon; Need to design studies that are much larger than the usual placebo controlled studies.

  • AIDS: The Battle Rages On. Heagarty, Margaret C. // Issues in Science & Technology;Summer2003, Vol. 19 Issue 4, p39 

    Focuses on the AIDS epidemic in the U.S. Beginning of the AIDS epidemic; Drugs tested for the treatment of the disease; Scientific advances in AIDS disease.

  • Maraviroc. Girotto, Jennifer E. // Formulary;Oct2007, Vol. 42 Issue 10, p601 

    Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. The use of maraviroc is associated with significant decreases in HIV viral load and increases in CD4 counts in antiretroviral treatment-experienced patients with CCR5-tropic virus when used as an add-on to...

  • Some Design Issues in Trials of Microbicides for the Prevention of HIV Infection. Fleming, Thomas R.; Richardson, Barbra A. // Journal of Infectious Diseases;8/15/2004, Vol. 190 Issue 4, p666 

    Trials for the prevention of human immunodeficiency virus (HIV) infection that evaluate microbicides provide significant design challenges. Three of these design issues deserve more careful consideration. The first issue relates to the benefits of using both blinded and unblinded control groups...

  • HIV vaccine called 'tantalizingly encouraging'.  // Contemporary Sexuality;Nov2009, Vol. 43 Issue 11, p9 

    The article reports that an HIV vaccine named RV 144 has displayed signs of limited effectiveness in preventing the disease. Medical doctor (MD) Richard Horton commented on the results of the six-year clinical study. The study was conducted by the Thai Ministry of Health, the U.S. Army and the...

  • GSK: experimental AIDS drug shows potent antiviral activity in human trial.  // PharmaWatch: Monthly Review;Sep2009, Vol. 8 Issue 9, p30 

    The article provides information on the study of a potential AIDS drug that lessens the HIV viral load. The experimental inhibitor from GlaxoSmithKline (GSK) shows potential to decrease the AIDS virus and states that GSK has the opportunity to develop the fixed dosage. It also discusses the...

  • Under the microscope.  // Echo Magazine;2/22/2007, Vol. 18 Issue 12, p38 

    This article discusses a U.S. Food and Drug Administration panel review in Washington, D.C. of a Pfizer HIV therapy called Maraviroc. The panel will convene in April, 2007 to assess its safety and effectiveness in combatting the virus that causes AIDS. This announcement coincides with a ban of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics